What is Entresto’s EMA exclusivity status?
Entresto (sacubitril/valsartan) has regulatory “exclusivity” in the EU through a mix of protections, most notably data/market exclusivity tied to the product’s first EU approval and related regulatory events. The European Medicines Agency (EMA) itself does not publish one simple, universal “exclusivity end date” for every scenario; the effective protection depends on the specific EU marketing authorization history (including any extensions), and on separate patent/ SPC coverage.
When does Entresto’s EU market exclusivity end (and what does it depend on)?
In practice, the date people usually look for is the end of the product’s EU data and/or market exclusivity (the period during which generic/biosimilar applicants generally face regulatory barriers), which depends on:
- The date of the first EU marketing authorization for Entresto.
- Whether any subsequent “major” authorizations or line extensions affected exclusivity.
- Whether the product benefited from any protection extensions that can apply under EU rules for certain kinds of approvals and pediatric/other regulatory milestones.
Because your question asks specifically about “EMA exclusivity,” the key is to identify the exact Entresto marketing authorization and the relevant exclusivity category (data vs market) tied to that authorization.
How to find the exact exclusivity end date for Entresto in EMA records
To get the precise end date, you normally check the EMA and EU regulatory sources that track exclusivity. The workflow is:
1. Look up Entresto’s EU marketing authorization in the EMA product information and identify the authorization details.
2. Use EU exclusivity/SPC tooling (commonly via EU “regulatory exclusivity” databases used by law firms and regulators) to match that authorization to the relevant protection type and expiry.
3. Confirm whether you’re asking about:
- regulatory exclusivity for the marketing authorization, or
- patent/SPC expiry (often what actually blocks generics in court).
If you share the strength you care about (e.g., tablets vs sachets) or the EU authorization ID (or the country/CHMP approval date you’re using), I can help narrow which exclusivity record to pull and what to compare.
How EMA exclusivity differs from patents and SPCs (and why it matters)
Even after regulatory exclusivity ends, patents and (in many cases) supplementary protection certificates (SPCs) can still block generic entry. So the earliest practical date for competitors often ends up being whichever is later:
- the regulatory exclusivity expiry, or
- the patent/SPC expiry for sacubitril/valsartan or formulation/use claims.
That’s why two “expiry dates” are often discussed: one from regulatory exclusivity and one from the patent estate/SPC.
What do companies usually look for when trying to launch a generic after exclusivity?
When generic companies assess entry timing, they check:
- whether they can submit for approval during exclusivity (submission timing may differ from launch timing),
- whether any “regulatory gaps” exist once exclusivity ends,
- and whether they can rely on carve-outs (for example, if switching to another indication or using different evidence pathways is permitted), though product-specific constraints apply.
Are there different exclusivities for different Indications, formulations, or authorizations?
Yes. If Entresto later gains additional authorized indications or new formulations under a separate regulatory pathway, the exclusivity landscape can change. That means a generic competitor may face different timing depending on which specific claim/indication they plan to launch under.
If you tell me one detail, I can give a concrete date
To provide the exact EMA/EU exclusivity expiry date you want (rather than a general explanation), tell me one of the following:
- the EU marketing authorization date you’re using, or
- the specific Entresto product/strength (e.g., tablets vs oral suspension if applicable), or
- the exact phrasing you saw (e.g., “data exclusivity,” “market exclusivity,” “8+2+1,” etc.), or
- the country (EU member state) where you want the practical launch timing.
Sources
None provided.